Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
Earnings at CarMax miss analysts’ estimates, Alpine Immune Sciences is being acquired by Vertex Pharmaceuticals for $4.9 billion in cash, Robinhood stock is downgraded, and Nike receives an upgrade.